Hongyun Jia

Hongyun Jia

Auto-generated profile, based on publicly available information

Hongyun Jia

Department of Clinical Laboratory, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2014 in BMC Cancer
Verified
Journal Article
Open access
PDF file
GSGang Shen
Gang Shen
YLYe Lin
Ye Lin
XYXuewei Yang
Xuewei Yang
JZJing Zhang
Jing Zhang
ZXZhe Xu
Zhe Xu
HJHongyun Jia
Hongyun Jia
Metastasis is responsible for the rapid recurrence and poor survival of malignancies. Epithelial-mesenchymal transition (EMT) has a critical role in metastasis. Increasing evidence indicates that EMT can be regulated by microRNAs (miRNAs). The aim of this study was to investigate the role of miR-26b in modulating epithelial-mesenchymal transition (EMT) in hepatocellular carcinoma (HCC), as well as to identify its underlying mechanism of action.

3 October 2014 in Carcinogenesis
Verified
Journal Article
Open access
PDF file
GSGang Shen
Gang Shen
XRXiaoxiang Rong
Xiaoxiang Rong
JZJianbo Zhao
Jianbo Zhao
XYXuewei Yang
Xuewei Yang
HLHaibo Li
Haibo Li
HJHongyun Jia
Hongyun Jia
A growing amount of evidence supports that microRNA (miRNA) dysregulation is involved in cancer progression by directly downregulating multiple targets. Elucidating the underlying mechanism of miRNA in carcinogenesis may improve diagnostic and therapeutic strategies for malignancy. In the current study, we found that miR-105 expression was markedly downregulated in both hepatocellular carcinoma (HCC) cell lines and clinical HCC tissues, compared with normal human hepatocyte and adjacent non-cancerous tissues, respectively. Ectopic miR-105 expression suppressed, whereas inhibiting miR-105 promoted the proliferation and tumorigenicity of HCC cells both in vitro and in vivo. Furthermore, we demonstrated that miR-105 could deactivated the phosphoinositide 3-kinase (PI3K)/AKT signaling pathway by downregulating insulin receptor substrate-1, 3-phosphoinositide-dependent protein kinase-1 and AKT1 directly, resulting in increasing cyclin-dependent kinase inhibitors 1A and 1B (p21Cip1 and p27Kip1) and decreasing cyclin D1 expression in HCC. Therefore, our results suggest that miR-105 functions as a potential tumor suppressor by inhibiting the PI3K/AKT signaling pathway and might represent a potential therapeutic target for HCC patients.

1 October 2008
Verified
Conference Paper
Closed access
Wei HuaWei Hua
Wei Hua
MCMing Cheng
Ming Cheng
HJHongyun Jia
Hongyun Jia
XFXiaofan Fu
Xiaofan Fu
Flux-switching and doubly-salient brushless motors are both novel PM machines having magnets in the stator instead of rotor with outstandingly different static characteristics, especially on the PM flux-linkage waveform, namely, the unipolar and quasi-trapezoidal one for the doubly-salient PM motor, whereas bipolar and sinusoidal one for the flux-switching PM motor, which inevitably results in the distinction in the toque capabilities of both motors. In this paper, based on the theoretical analysis and finite element calculation, a comprehensive comparison on the torque performance of the two motors are investigated under five classical working conditions, in which the flux-switching PM motor is operated in brushless AC mode, while the doubly-salient PM motor is run in brushless DC mode. It is found that the flux-switching PM motor has superior torque capability to that of the doubly-salient PM counterpart, which is verified by both the finite element analysis and experimental results.

16 February 2009 in BMC Cancer
Verified
Journal Article
Open access
PDF file
JWJiangxue Wu
Jiangxue Wu
XXXia Xiao
Xia Xiao
HJHongyun Jia
Hongyun Jia
JCJiemin Chen
Jiemin Chen
YZYinghui Zhu
Yinghui Zhu
WHWenlin Huang
Wenlin Huang
Background: We previously found that r-hu-IFNγ exerts a potent anti-tumor effect on human nasopharyngeal carcinoma xenografts in vivo. Considering the fact that the clinical use of recombinant IFNγ is limited by its short half-life and systemic side effects, we developed a recombinant adenovirus, Ad-IFNγ. Methods: Dynamic distribution of the adenovirus vector and expression of IFNγ were evaluated by Q-PCR and ELISA after intratumoral administration of Ad-IFNγ into CNE-2 xenografts. Results: Ad-IFNγ DNA was mainly enriched in tumors where the Ad-IFNγ DNA was injected (P < 0.05, compared to blood or parenchymal organs), as well as in livers (P < 0.05). Concentrations of Ad-IFNγ DNA in other organs and blood were very low. Intratumoral Ad-IFNγ DNA decreased sharply at high concentrations (9 × 105 copies/μg tissue DNA), and slowly at lower concentrations (1.7–2.9 × 105 copies/μg tissue DNA). IFNγ was detected in the tumors and parenchymal organs. The concentration of IFNγ was highest in the tumor (P < 0.05), followed by the liver and kidney (P < 0.05). High-level intratumoral expression of IFNγ was maintained for at least 7 days, rapidly peaking on day 3 after injection of Ad-IFNγ DNA. Conclusion: An IFNγ gene delivered by an adenoviral vector achieved high and consistent intratumoral expression. Disseminated Ad-IFNγ DNA and the transgene product were mainly enriched in the liver.

23 July 2015 in Tumor Biology
Verified
Journal Article
Closed access
PDF file
JZJing Zhang
Jing Zhang
HJHua Jiang
Hua Jiang
WXWenfei Xia
Wenfei Xia
YJYizhou Jiang
Yizhou Jiang
XTXiaoyun Tan
Xiaoyun Tan
GSGang Shen
Gang Shen

25 October 2022 in Disease Markers
Verified
Journal Article
Open access
PDF file
SHSicong Huang
Sicong Huang
YCYi-Mei Chen
Yi-Mei Chen
YHYing-Yu Hu
Ying-Yu Hu
YSYong-Jie Shi
Yong-Jie Shi
QXQi-Wen Xiao
Qi-Wen Xiao
HJHong-Yun Jia
Hong-Yun Jia
Backgound. Multiple patients with hepatocellular carcinoma (HCC) received sorafenib therapy presented primary or secondary chemoresistance. The underlying mechanisms of chemoresistance are rather vague, ferroptosis is a new kind of cell death, and its discovery provides new opportunities to overcome sorafenib resistance. Therefore, it is essential to investigate the regulators of ferroptosis and implement a corresponding therapy strategy. Methods and Results. The levels of MCF2L were detected by PCR and western blotting assay. The effect of MCF2L on ferroptosis was confirmed by MTT, colony formation assay, Brdu, in vivo animal experiment, and the content of Iron, GSH, ROS, and MDA. The underlying mechanisms were explored by PCR, western blotting, and affinity precipitation assay. Our findings demonstrated that MCF2L is remarkedly upregulated in HCC tissues, and sorafenib can induce the levels of MCF2L, suggesting that MCF2L might function in sorafenib resistance of HCC. Further analysis showed that downregulation of MCF2L enhances HCC cell death induced by sorafenib, and ferroptosis inhibitor can reverse this process. Subsequent experiments showed that downregulation of MCF2L elevates the content of Iron, ROS, and MDA, which are all indicators of ferroptosis. Finally, mechanism analysis showed that MCF2L regulates the PI3K/AKT pathway in a RhoA/Rac1 dependent manner. Conclusions. Our study showed that targeting MCF2L may be a hopeful method to overcome sorafenib-resistance through inducing ferroptosis in HCC.